1. 880PSubgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy. (23rd October 2018) Authors: Procopio, G; Cognetti, F; Miceli, R; Milella, M; Mosca, A; Chiuri, V E; Bearz, A; Morelli, F; Ortega, C; Atzori, F; Passalacqua, R; Ratta, R; de Braud, F G M; Cappelletti, V; Verzoni, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 882PPotent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts). (23rd October 2018) Authors: Verzoni, E; Ferro, S; Procopio, G; Cova, A; Ratta, R; Raimondi, A; Sepe, P; Squarcina, P; Lalli, L; Huber, V; Rinchai, D; Bedognetti, D; Rivoltini, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗